Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 4/20 | 0.48 |
| ▸ | SPHK1 | Q9NYA1 | 2/20 | 0.47 |
| ▸ | GUSB | P08236 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 3/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 3/20 | 0.44 |
| ▸ | S1PR2 | O95136 | 2/20 | 0.44 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR5 | Q9H228 | 2/20 | 0.44 |
| ▸ | GLB1 | P16278 | 4/20 | 0.44 |
| ▸ | GBA2 | Q9HCG7 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19837679 | 1.00 | GBA1 (0.48) | GBA1SPHK1GUSBALDH1A1S1PR1 | |
| SCHEMBL11870431 | 1.00 | GBA1 (0.48) | GBA1SPHK1GUSBALDH1A1S1PR1 | |
| SCHEMBL3411264 | 1.00 | GBA1 (0.48) | GBA1SPHK1GUSBALDH1A1S1PR1 | |
| SCHEMBL2233321 | 1.00 | — | — | |
| SCHEMBL27892522 | 0.97 | GBA1 (0.47) | GBA1SPHK1GUSBALDH1A1S1PR1 | |
| SCHEMBL1463931 | 0.97 | — | — | |
| SCHEMBL294556 | 0.91 | GBA1 (0.43) | GBA1SPHK1GUSBALDH1A1S1PR1 | |
| SCHEMBL14621071 | 0.89 | — | — | |
| SCHEMBL1031928 | 0.89 | — | — | |
| SCHEMBL7127893 | 0.89 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104428331-B | Active energy beam polymer resin composition and the laminated body for using the resin combination | 东洋油墨SC控股株式会社 | 2019-02-15 | — | — | CN | disclosed |
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | GILEAD PHARMASSET LLC | 2017-09-21 | — | — | US | disclosed |
| EP-0387567-B1 | Amphoteric polyelectrolyte, method for production thereof, and organic sludge dehydrater | NIPPON CATALYTIC CHEM IND (JP) | 1996-05-01 | — | — | EP | disclosed |
| US-5284909-A | Emulsion polymerizing anionic monomer or mixture with nonionic monomer in water, surfactant, hydrophobic solvent with free radical catalyst, reacting polymer with alkylenimine, acidifying with monobasic acid | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5194515-A | Addition polymerization of acrylic acid with other monomers and modified with alkylene imine by aminoalkylation | NIPPON SHOKUBAI KAGAKU KOGYO CO., LTD. (JP) | 1993-03-16 | — | — | US | disclosed |
| EP-0387567-A2 | Amphoteric polyelectrolyte, method for production thereof, and organic sludge dehydrater | NIPPON SHOKUBAI CO., LTD. (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-3953391-A | ALKYLENEIMINE-MODIFIED ACRYLIC COPOLYMERSACID | PPG INDUSTRIES, INC. (US) | 1976-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170267694-A1 | CRYSTALLINE FORMS OF AN ANTIVIRAL COMPOUND | HAVCR2, IFNAR1, ZC3HAV1 | GBA1 277/4885SPHK1 4532/4885GUSB 4723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.